Table 1.
Breadth of S20 Antiviral Activitya
| virus strain | IC50 (μM) | 95% CIb | IC90 (μM) | 95% CIb |
|---|---|---|---|---|
| A/WSN/1933 (H1N1) | 0.08 | 0.02–0.16 | 0.2 | 0.01–0.8 |
| A/Puerto Rico/8/1934 (H1N1) | 0.8 | 0.18–3.35 | 2.5 | 1.38–3.9 |
| A/California/04/2009 (H1N1) | 0.15 | 0.02–0.37 | 1.8 | 0.93–2.76 |
| A/Vietnam/1203/2004 (H5N1) | 0.08 | 0.01–0.24 | 4 | 1.7–6.1 |
| A/Hong Kong/1/1968 (H3N2) | >10 | NA | >10 | NA |
| A/Panama/2007/1999 (H3N2) | >10 | NA | >10 | NA |
| A/Wyoming/03/2003 (H3N2) | >10 | NA | >10 | NA |
| A/Victoria/361/2011 (H3N2) | >10 | NA | >10 | NA |
| A/Perth/16/2009 (H3N2) | >10 | NA | >10 | NA |
| B/Yamagata/16/1988 | >20 | NA | >20 | NA |
| vesicular stomatitis virus | >20 | NA | >20 | NA |
a
Inhibitory potencies of S20 against a range of influenza A virus subtypes, influenza B virus, and VSV. All infections were performed in A549 cells, with the exception of influenza B virus infection, which was performed in MDCK cells.
b
95% confidence intervals reported as (lower limit – upper limit).